<DOC>
	<DOCNO>NCT02606526</DOCNO>
	<brief_summary>BCG vaccination may non-specific effect ( NSE ) i.e. , additional benefit childhood morbidity mortality separate vaccine 's effect incidence disseminate tuberculosis . Though available literature mostly observational study design , fraught controversy , BCG vaccination birth , high risk population HIV expose child , may protect infant serious infection TB . Yet , study indicate give BCG later infancy , immune system mature , may offer even great protection . The appropriate timing BCG vaccination could therefore revision . This study therefore compare BCG vaccination birth BCG vaccination 14 week age HIV expose ( HE ) baby . Methods : This individually randomized clinical trial 2,200 HIV expose infant . The intervention intra-dermal administration 0.05 ml BCG vaccine within 24 hour birth comparator intra-dermal administration 0.05ml BCG vaccine 14 week age . The main study outcome include : 1 . Severe illness first 14 week life , 2 . TNF , IL‑1b , IL-6 IFN-γ response mycobacterial non-mycobacterial antigen 3 . Severe illness first 14-52 week 0-52 week life . The study carry two health Center IIIs health center IV Uganda . Implications : A well-timed BCG vaccination could important additional benefit HE infants . This trial could inform development programmatically appropriate timing BCG vaccination HE infants .</brief_summary>
	<brief_title>Early Versus Late BCG Vaccination HIV-1 Exposed Infants Uganda Uganda</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<criteria>A baby bear participate study clinic include s/he : 1. mother positive HIV test ( ELISA rapid test ) 2. receive periexposure prophylaxis part standard/national guideline Uganda 3. mother legal age participation clinical research study Uganda emancipate minor 4. mother/caregiver resides within study area , intend move area next 4 month likely traceable 12 month 5. mother/caregiver give informed consent random assignment either two trial arm 6. mother receive antiretroviral therapy ( ART ) least 4 week A newborn child exclude she/he : 1. serious congenital malformation ( ) 2. severe illness require hospitalization 3. birth weight &lt; 2.0 kg 4. mother participate another clinical trial day enrolment mother participate another clinical trial within next month . 5. mother household member symptom sign tuberculosis day enrolment 6. severely ill mother ( ) condition ( ) require hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Day</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>